Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Ulaner

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Journal of the American College of Radiology : JACR|May 26, 2023
ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update, Katherine A Klein, Maddi Kocher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast CancerRandy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
Journal of the American College of Radiology : JACR|February 19, 2026
ACR Appropriateness Criteria® Breast Implant Evaluation: Update 2025, Debbie L Bennett, Ann Brown, et al.
Journal of the American College of Radiology : JACR|March 21, 2026
ACR Appropriateness Criteria® Staging and Follow-Up of Adrenal Cancer, Silvia D Chang, Cassandra Jeavons, et al.
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer, Elizabeth S McDonald, John R Scheel, et al.
Journal of the American College of Radiology : JACR|November 6, 2019
ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women, Alana A Lewin, Linda Moy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Journal of the American College of Radiology : JACR|November 6, 2018
ACR Appropriateness Criteria<sup>®</sup> Evaluation of the Symptomatic Male Breast, Bethany L Niell, Ana P Lourenco, et al.
Blood|July 7, 2017
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosisMatthias Papo, Eli L Diamond, Fleur Cohen-Aubart, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Journal of the American College of Radiology : JACR|May 26, 2023
ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update, Katherine A Klein, Maddi Kocher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast CancerRandy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
Journal of the American College of Radiology : JACR|February 19, 2026
ACR Appropriateness Criteria® Breast Implant Evaluation: Update 2025, Debbie L Bennett, Ann Brown, et al.
Journal of the American College of Radiology : JACR|March 21, 2026
ACR Appropriateness Criteria® Staging and Follow-Up of Adrenal Cancer, Silvia D Chang, Cassandra Jeavons, et al.
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer, Elizabeth S McDonald, John R Scheel, et al.
Journal of the American College of Radiology : JACR|November 6, 2019
ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women, Alana A Lewin, Linda Moy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Journal of the American College of Radiology : JACR|November 6, 2018
ACR Appropriateness Criteria<sup>®</sup> Evaluation of the Symptomatic Male Breast, Bethany L Niell, Ana P Lourenco, et al.
Blood|July 7, 2017
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosisMatthias Papo, Eli L Diamond, Fleur Cohen-Aubart, et al.
Pageof 16